Biogen’s experimental therapy litifilimab, also called BIIB059, significantly reduced skin disease activity in adults with cutaneous lupus erythematosus (CLE), according…
Articles by Marta Figueiredo, PhD
The strongest genetic risk factor of systemic lupus erythematosus (SLE), HLA-DRB1*03:01, generates an abnormal protein that, in the presence of…
Thermo Fisher Scientific has received regulatory authorization in the U.S. to market its EliA Rib-P blood test, designed to…
The Lupus Research Alliance (LRA) has awarded a total of $2.1 million to five research projects from underrepresented minority…
Lupus Therapeutics, an affiliate of the Lupus Research Alliance (LRA), announced that it is working to design and run a…
Enzo Biochem’s investigational compound SK1‑I lessened autoimmune and inflammatory responses, including in the kidney, in a mouse model…
Upper limb exercise lowers pain and improves hand function, daily activity performance, and quality of life in people with…
DNA vaccination with heat shock protein 70 (HSP70) eased inflammation, boosted immune regulation, delayed kidney disease and prolonged life…
Pregnancy is not associated with increased chronic damage in women with systemic lupus erythematosus (SLE), regardless of when they’re…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to itolizumab as a potential therapy for lupus nephritis, a common and…